Psyched Wellness Receives DTC EligibilityCybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug ApplicaRritual Appoints Sarton Molnar-Fenton, Vice President Sales USATryp Therapeutics Announces Listing on OTCQB and DTC EligibilityPure Extracts Dual Vertical Approach Incorporating Cannabis and Psychedelic Compounds Is Starting To Pay OffTryp Therapeutics Appoints Greg McKee as Chief Executive OfficerPsyence Group and Pure Extracts Sign JV Letter of Intent for the Extraction of Psilocybin from Psychedelic Mushrooms andCybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United StatesPsyched Wellness Initiates Study on AME-1 Extract for Gut HealthRritual Superfoods to Launch Product Line in Rite Aid Stores – NationwideMushroomStocks.com Deep Dive: Tryp Therapeutics (CSE:TRYP)Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (Field Trip Has A Warchest Of Cash To Propel R&D and M&A Moving ForwardCybin Inc. Is Rapidly Progressing Its Drug Development Program With Plenty On The HorizonPure Extracts Orders Cutting Edge Vitalis Cosolvent Injection SystemTryp Therapeutics Announces Provisional Patent Filing For Improved Administration of PsychedelicsCybin Progresses Two Psychedelic Investigational New Drug (“IND”) Candidates and Announces Completion of Its 20th PrRritual Announces Successful Completion of Second Full Scale Manufacturing Run and Commencement of Third Full Scale ManuNuminus Wellness Is Taking Strides To Advance Its R&D Business UnitRritual Announces Successful Launch of US Facing E-Commerce Website and Provides Corporate Update
Back

Cybin Inc. Is Focused On Taking A Quantitative Approach To Tackling Depression

Feb 17, 2021 • 10:15 AM EST
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Earlier this month, Cybin Inc. (NEO:CYBN) issued an operational update after it reported third quarter financial results and this is an opportunity that we continue to closely follow.

The biotech firm is focused on advancing psychedelic therapeutics through clinical trials and commercializing treatments for mental health disorders. We classify Cybin as an industry leader and has been executing on a multi-faceted growth strategy. Since inception, the company has raised approximately $90 million and is well positioned to capitalize on unique growth initiatives.

From building out an extensive intellectual property (IP) portfolio to making strategic acquisitions, Cybin’s management team is executing on inorganic and organic growth initiatives and we are favorable on the direction the leadership team is taking the business.

So far, Cybin has submitted 10 patent applications that cover novel molecules, delivery systems, deuterated tryptamines, and phenethylamines. We are favorable on the focus on IP and believe that its acquisition of Adelia Therapeutics further expanded the IP portfolio and diversified the development pipeline.

Through a strategic partnership with Kernel, Cybin has access to neuroimaging technology that allows it to potentially quantify brain activity in real time during psychedelic experiences. We believe that initiatives like this have further differentiated Cybin from its peers and will monitor how this aspect of the business advances from here.

Going forward, Cybin plans to use its resources and cash to advance clinical trials, novel molecule programs, and technologies that support patient care. We are favorable on how Adelia strengthens Cybin’s IP strategy, pre-clinical drug development expertise, presence in the US, and scientific team. The acquisition included novel psychedelic molecules that further diversify the company’s development portfolio and we will monitor how the combined company is able to execute on key growth initiatives.

At current levels,we believe that Cybin has a favorable risk-reward profile and are especially bullish on the strength of its balance sheet and IP portfolio. Going forward, we expect the company to announce major developments as it relates to its growth strategy and is an opportunity that we excited about.

If you are interested in learning more about Cybin and how it is positioned to capitalize on the psychedelic therapy market, please send an email to support@technical420.com to be added to our distribution list.

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Comments

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link